Prevalence, pathophysiology, prediction and health-related quality of life of long COVID: study protocol of the longitudinal multiple cohort CORona Follow Up (CORFU) study

Chahinda Ghossein-Doha,1,2 Marieke S J N Wintjens,3,4 Emma B N J Janssen,2,5 Dorthe Klein,3,6 Stella C M Heemskerk,3,6 Folkert W Asselbergs,2,5 Erwin Birnie,3,10 Gouke J Bonsel,9 Bas C T van Bussel,6,11 Jochen W L Cals,1,2,12,13 Hugo Ten Cate,14,15 Juanita Haagsma,16 Bena Hemmen,13,17 Iwan C C van der Horst,10,2,18 Bastiaan L J H Kietselaer,19,20 Frederikus A Klok,21 Martijn D de Kruijf,22 Marijke Linschoten,7,23 Susanne van Santen,11,13 Kevin Vernooy,12,14 Loes H Willems,24 Rosa Westerborg,22 Michiel Warle,24 Sander M J van Kuijk3,13

ABSTRACT

Introduction The variety, time patterns and long-term prognosis of persistent COVID-19 symptoms (long COVID-19) in patients who suffered from mild to severe acute COVID-19 are incompletely understood. Cohort studies will be combined to describe the prevalence of long COVID-19 symptoms, and to explore the pathophysiological mechanisms and impact on health-related quality of life. A prediction model for long COVID-19 will be developed and internally validated to guide care in future patients.

Methods and analysis Data from seven COVID-19 cohorts will be aggregated in the longitudinal multiple cohort CORona Follow Up (CORFU) study. CORFU includes Dutch patients who suffered from COVID-19 at home, were hospitalised without or with intensive care unit treatment, needed inpatient or outpatient rehabilitation and controls who did not suffer from COVID-19. Individual cohort study designs were aligned and follow-up has been synchronised. Cohort participants will be followed up for a maximum of 24 months after acute infection. Next to the clinical characteristics measured in individual cohorts, the CORFU questionnaire on long COVID-19 outcomes and determinants will be administered digitally at 3, 6, 12, 18 and 24 months after the infection. The primary outcome is the prevalence of long COVID-19 symptoms up to 2 years after acute infection. Secondary outcomes are health-related quality of life (eg, EQ-5D), physical functioning, and the prevalence of thromboembolic complications, respiratory complications, cardiovascular diseases and endothelial dysfunction. A prediction model and a patient platform prototype will be developed.

Ethics and dissemination Approval was obtained from the medical research ethics committee of Maastricht University Medical Center+ and Maastricht University (METC 2021-2990) and local committees of the participating cohorts. The project is supported by ZonMW and EuroQol Research Foundation. Results will be published in open access peer-reviewed scientific journals and presented at (inter)national conferences.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Survivors from seven existing COVID-19 cohorts will be asked to participate in CORona Follow Up (CORFU); clinical data will be aggregated and enriched with results from questionnaires on symptoms, health-related quality of life and societal impact at synchronised follow-up moments to estimate the prevalence and pathophysiological mechanisms of long COVID-19, the impact on health-related quality of life and their key determinants.

⇒ A control group of Dutch participants from the general population, who did not suffer from COVID-19, will be included for comparison with regard to the prevalence and health-related quality of life.

⇒ The heterogeneous cohort populations enable CORFU to investigate study aims in various subgroups (eg, home isolated vs hospitalised patients) and test pathophysiological hypotheses.

⇒ An over-representation of (former) COVID-19 patients admitted to the hospital (ward or intensive care unit) might exist, potentially resulting in over-representation of more severe cases of long COVID-19, all of which will be considered in the analysis and presentation.

INTRODUCTION

The WHO defines the post-COVID-19 condition, also known as long COVID, as a
condition that occurs 3 months from the onset of infection, with symptoms that last for at least 2 months and are not explained by an alternative diagnosis.\textsuperscript{1} The prevalence of long COVID symptoms varies in literature, ranging from 40\% to 68\% six months after COVID diagnosis and up to 49\% after 12 months.\textsuperscript{3,4} Frequently reported symptoms include fatigue, shortness of breath, headache, cognitive impairment (eg, concentration problems), muscle weakness and joint stiffness.\textsuperscript{5–8} Persistent long COVID symptoms are associated with poorer health-related quality of life.\textsuperscript{9,10} Furthermore, there is an increased risk of incident cardiovascular complaints and cardiovascular diseases for people who suffered from COVID beyond the first month of infection.\textsuperscript{11,12} Next to the physical and mental symptoms of long COVID, there is a psychological and emotional impact which might be induced by the social restrictions and financial impact (including income uncertainty) during the pandemic.\textsuperscript{13,14}

Long COVID occurs both in patients with mild and with severe acute course. So far, the severity of the acute infection seems related to the risk of long COVID symptoms.\textsuperscript{5–17} Additional factors affecting the risk of long COVID are the presence of one or more pre-existing comorbidities and being a middle-aged female.\textsuperscript{16,18,19} Whether the type of SARS-CoV-2 strain relates to long COVID is unknown.

In patients suffering from critical COVID-19 in the intensive care unit (ICU), long COVID-19 symptoms may coexist with, or be indistinguishable from, the post-ICU syndrome, defined as newly emerging physical, cognitive or mental limitations after suffering from severe disease during ICU stay.\textsuperscript{20}

Due to the novelty of COVID-19, studies focus on short term physical functioning and mental well-being. However, less is known about persisting COVID-19 symptoms up to 2 years after acute infection, and the factors determining prognosis (if any). More knowledge will facilitate long COVID-19 (health)care and follow-up (eg, specific services such as (lung) rehabilitation and occupational support) for specific patient groups, guided by prognostic information. This knowledge may translate into national and international guidelines on the prevention, diagnosis and treatment of long COVID-19.

This paper describes the protocol of the CORona Follow Up (CORFU) study: a national longitudinal, multiple cohort study that aggregates data of existing cohorts and enriches these data with repeated digital follow-up questionnaires on long COVID symptoms and health-related quality of life up to 2 years after the first infection. Five aims, summarised in four work packages (WP), have been formulated:

- **WP1:**
  a. To describe the prevalence, severity, time patterns and duration of long COVID symptoms up to 2 years after acute infection and their relationship with health-related quality of life.

- **WP2:**
  To investigate the pathophysiological mechanisms that may cause long COVID symptoms and the role of vulnerability/resilience factors.

- **WP3:**
  To develop and validate a prediction model for the persistence of symptoms, stratified by severity of COVID.

- **WP4** (in collaboration with EuroQol Research Foundation):
  Develop a patient platform prototype where patients can digitally consult their reported outcomes, compare them with previous outcomes, relate to reference information and find reported information that fits their situation.

**METHODS AND ANALYSIS**

**Study design**

The CORFU study is a longitudinal multiple cohort study that aggregates data of seven existing Dutch COVID-19 cohorts, prospectively complemented with routinely collected outcome data on long COVID-19, with a maximum follow-up of 24 months after initial infection. Data will be collected between 1 October 2021 and 31 December 2022.

All cohorts were initiated and designed to conduct COVID-19 research. Six cohorts will collect data according to their individual clinical focus (figure 1). In addition, participants from the community-based POPulation health impact of the COVID-19 pandemic (POPCorn) cohort will serve as a control group as this cohort partly consists of controls who did not suffer from COVID-19. However, at present, many of the POPCorn participants could have suffered from (mild) COVID-19. Therefore, all POPCorn participants will be asked repeatedly to report whether or not they suffered from (confirmed or suspected) COVID-19 and only the participants who did not suffer from COVID-19 will serve as a control. In the POPCorn cohort, similar outcome data will be collected as in the other participating cohorts. As CORFU is open to new collaborations, it is likely that additional cohorts will join CORFU in the future. Participation of new cohorts will be reported when presenting the CORFU study findings.

The cohort-specific follow-up measurements will be complemented by a repeatedly administered CORFU questionnaire covering the full array of long COVID symptoms, health-related quality of life effects and their key determinants. Furthermore, (clinical) data that have already been collected in the participating cohorts during the acute COVID stage will be used to investigate the CORFU study aims.

**Participants**

The study population consists of Dutch (former) COVID-19 survivors and non-COVID-19 controls, who have been included in one of the cohorts. Former COVID-19 cases are either confirmed by a positive PCR
test for SARS-CoV-2 and/or a positive CT scan of the chest based on the COVID-19 Reporting and Data System (CO-RADS) Score (score 4–5 by a radiologist), or likely based on self-reported questionnaires (ie, unspecified positive COVID-19 test or the presence of COVID-19-related symptoms). The study population is categorised into five subgroups:

- Patients who suffered from confirmed COVID-19 admitted to the hospital ward.
- Patients who suffered from confirmed COVID-19 admitted to the ICU.
- Patients who suffered from either confirmed or likely (ie, self-reported) COVID-19 at home.
- Patients who suffered from confirmed COVID-19 and needed inpatient or outpatient rehabilitation after infection at home or in the hospital (ward and/or ICU).
- Controls who (likely, ie, self-reported) did not suffer from COVID-19.

Adult participants (≥18 years) with confirmed or suspected COVID-19 and non-COVID-19 controls who sufficiently master the Dutch language will be eligible for inclusion in the CORFU study. No additional exclusion criteria will be used. In addition to provided consent or no declared objection for initial cohort participation, all participants will be asked to give written and/or digital informed consent prior to the first CORFU follow-up questionnaire (if not already covered by the specific cohort inclusion scheme).
Data sources: COVID-19 cohorts
Data will be derived from the following seven COVID-19 cohorts:
► Adelante cohort.²¹
► Bernhoven early detection of vascular damage after COVID-19 (COVAS) cohort.²²
► Cardiac complications in patients with COVID-19 (CAPACITY-COVID) cohort.²³²⁴
► Dutch COVID-19 and Thrombosis Consortium cohort.²⁵
► MaastrICht cohort.²⁶
► POPulation health impact of the COVID-19 pandemic (POPCOrn) cohort.²⁷
► ZuydErLand COVID-19 regiStry (ELVIS) cohort.²⁸

Figure 1 shows the aims, study population and outcomes of each cohort. Electronic case report forms will be used to facilitate data aggregation in order to answer the CORFU study aims. Moreover, the study designs of the majority of the individual cohorts have been aligned in the conceptualisation phase. This includes synchronisation of the follow-up moments during which CORFU data will be collected prospectively, as well as a synchronisation of the additional (clinical) data that will be collected in the individual cohorts, including their level of measurement.

In May 2022, the total source population of the participating cohorts included 12,631 participants. However, the total number of CORFU participants will be lower, as it depends on the survival and the CORFU response rates in the individual cohorts, as well as the number of participants which are included in multiple cohorts. In addition, five out of seven cohorts are prospectively including new patients. The CORFU study population will be described in more detail when reporting the study findings.

Data collection: CORFU questionnaire
Besides the clinical data collection in the cohorts, the CORFU questionnaire will be periodically administered to study participants up to 2 years after suffering from COVID-19. The CORFU questionnaire is based on an internationally developed basic questionnaire on persistent symptoms after COVID-19.²⁷ It is digitally adaptive and includes questions on the following outcomes and determinants:

Outcomes
► Long COVID symptoms, with a five-level severity scale.
► Health-related quality of life (EuroQol 5 Dimenions 5 Levels (EQ-5D-5L), EuroQol Visual Analogue Scale (EQ-VAS)).
► Anxiety and depression (Hospital Anxiety and Depression Scale (HADS), Generalized Anxiety Disorder 2-item (GAD-2), Patient Health Questionnaire-2 (PHQ-2)).
► Social participation and connectedness.
► Experienced stigmatisation and resilience.
► Consequences for employment status and personal income.

Determinants
► COVID-19-related factors (eg, date of diagnosis and/or clinical admission, severity, wave as surrogate for SARS-CoV-2 strain).
► Sociodemographic and diversity factors (eg, age, sex, gender, socioeconomic).
► Presence of chronic disease or pre-existing vulnerability.
► Impact on healthcare access and experienced quality, healthcare avoidance and self-care.
► Vaccination status at the moment of acute infection.

The CORFU questionnaire will be digitally administered at 3, 6, 12, 18 and 24 months after COVID-19 via a web-based survey or, if requested, on paper. On an individual level, the follow-up moments on which the CORFU questionnaire will be administered depends on the date of first infection (diagnosis and/or admission). In retrospect, not all follow-up moments will apply to all participants. As the CORFU study duration is 15 months, participants will receive a maximum of three CORFU questionnaires. Completing the questionnaire takes, on average, 20–25 min, and participants will receive regular reminders to optimise the response rate.

As study participants were included at different time points in the COVID-19 pandemic, depending on their date of first infection, different contextual factors might apply such as lockdowns, the availability of testing material and testing policy, and the vaccination strategy at that time. These factors are presented in detail in online supplemental table S1.

Outcome variables
The primary outcome is the prevalence of long COVID symptoms up to 2 years after infection. Symptoms include, but are not limited to fatigue, muscle weakness, respiratory complaints, cardiovascular complaints, cognitive impairment, anxiety and depression. Secondary outcomes are health-related quality of life, physical functioning, and the prevalence of thromboembolic complications, respiratory complications, cardiovascular diseases and endothelial dysfunction.

Initially, the WHO definition will be used to define long COVID.³ Potential long COVID phenotypes as part of WP1 and other international developments within the field will also be further considered throughout the study.

Data management and data safety
The data will be stored and accessible according to Findability, Accessibility, Interoperability and Reusability (FAIR) data standards.²⁹ For this, we will apply a machine-readable metadata scheme. Two trusted third parties will administer the digital questionnaires in the individual cohorts: Durrer Center for Cardiovascular Research, Amsterdam, the Netherlands, and Triqs, Zwolle, the Netherlands. Durrer Center facilitates autonomous and secure data management and is founded by the Netherlands
Heart Institute. Triqs is an innovative research agency facilitating data collection through digital questionnaires.

The data flow is as follows. First, Durrer Center will receive participants’ contact details from the participating cohorts, check these for any flaws (eg, missing contact details and duplications) and encrypt the contact details except email prior to sharing these with Triqs. Next, Triqs will invite the participants for consent and, subsequently, for participation in the CORFU questionnaire. On consent, participants will digitally receive the questionnaires. After that, Triqs will store the resulting data records (still encrypted) and send these to Durrer Center. Durrer Center will decrypt and subsequently verify each data record and create a pseudoanonymised dataset which will be made available to the CORFU research group and the participating cohorts. As part of the data process, obligatory General Data Protection Regulation contracts will be created between the participating hospitals (care units), Durrer Center, Triqs and the CORFU study unit. In addition, data access agreements will be arranged between the CORFU study unit and the participating cohorts; poststudy secondary analysis of the survey data has been agreed on in collaboration with the EuroQol Research Foundation. Both Durrer Center and Triqs work processes and facilities meet the Dutch privacy legislation standards (International Organization for Standardization and NEDerlandse Norm (NEN) norms).

**WPs and data analysis**

This paragraph describes a generic outline of aims and methods of the WPs. Future manuscripts on CORFU WP findings will describe the aims and used methods in more detail. Table 1 displays the WPs and the corresponding aims and involved cohorts. Within all WPs, baseline data of participating cohorts will be described in detail, stratified by subgroup if necessary. Missing data will be imputed if the percentage of incomplete records exceeds 5% using multiple imputation with fully conditional specification. The number of imputations will be set to the percentage of incomplete records, and values will be drawn using predictive mean matching. The primary analyses of the WPs 1–3 aims will be performed with data from CORFU participants who (likely) suffered from COVID-19. Sensitivity analyses will be performed for the subgroup of participants who suffered from confirmed COVID-19 (ie, positive PCR test for SARS-CoV-2 and/or a CO-RADS Score of 4–5).

WP1 will investigate the first and second study aims. First, data of the seven cohorts will be aggregated and used to estimate the prevalence and severity of long COVID symptoms, expressed as a percentage with a 95% CI and as a distribution of severity scores at every follow-up moment. Next, the association between symptom severity and health-related quality of life will be quantified using linear regression analysis and repeated measurements analysis, adjusted for potential confounders. Finally, rehabilitation and paramedical support will be described using descriptive statistics. Analyses will be stratified by participant subgroups (ie, suffered from COVID at home, admitted to hospital ward, admitted to ICU). Furthermore, long COVID ‘phenotypes’ (ie, subtypes: patients with similar expressions of symptoms) will be estimated. Important phenotypes may depend on combinations of previously reported domains of symptoms (eg, respiratory, cardiovascular), but phenotypes may also depend on previously unidentified combinations. Clusters of patients will be estimated using unsupervised machine learning techniques with K-means and hierarchical clustering, which are data supportive and thereby not confirmatory (of prior hypotheses) in nature.

WP2 will investigate the third study aim. Each cohort will formulate specific long COVID research questions related to various pathophysiological mechanisms and

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Overview of the work packages, including study aims and cohorts</th>
</tr>
</thead>
<tbody>
<tr>
<td>WP</td>
<td>Aim</td>
</tr>
<tr>
<td>WP1</td>
<td>1. Describe the prevalence, severity, time patterns and duration of long COVID symptoms up to 2 years after acute infection and their relationship with health-related quality of life. 2. Describe the received rehabilitation and paramedical support in relation to the persisting symptoms and health-related quality of life.</td>
</tr>
<tr>
<td>WP2</td>
<td>3. Describe the pathophysiological mechanisms that may cause long COVID symptoms and the role of vulnerability/resilience factors.</td>
</tr>
<tr>
<td>WP3</td>
<td>4. Develop and validate a prediction model for the persistence of symptoms, stratified by severity of COVID-19.</td>
</tr>
<tr>
<td>WP4</td>
<td>5. Develop a patient platform prototype where patients can digitally consult their reported outcomes, compare them with previous outcomes, relate to reference information and find reported information that fits their situation.</td>
</tr>
</tbody>
</table>

Table 2 Overview of work package 2 (WP2) hypotheses on pathophysiological mechanisms that might cause long COVID symptoms

<table>
<thead>
<tr>
<th>Pathophysiological mechanism</th>
<th>Main research questions include, but are not limited to:</th>
<th>Cohort (minimally) involved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thromboembolic complications</td>
<td>1. What is the impact of venous thromboembolic complications on long-term functional outcomes in COVID-19 survivors?</td>
<td>DC&amp;TC</td>
</tr>
<tr>
<td>Cardiovascular diseases</td>
<td>2. What is the impact of myocardial damage during hospital ward or ICU stay due to COVID-19 on angina pectoris and dyspnoea over time?</td>
<td>CAPACITY-COVID</td>
</tr>
<tr>
<td>Endothelial dysfunction</td>
<td>3. What is the relationship between elevated inflammation parameters and persistent thrombo-inflammation, coagulation, microvascular and macrovascular dysfunction, and respiratory symptoms after COVID-19 disease?</td>
<td>COVAS</td>
</tr>
<tr>
<td>Multi organ failure</td>
<td>4. What is the impact of multiorgan failure during ICU stay on long-term functional outcomes and (health-related) quality of life in COVID-19 survivors?</td>
<td>MaastrICht</td>
</tr>
<tr>
<td>Pre-existing coronary atherosclerosis</td>
<td>5. What is the relationship between pre-existing clinical and subclinical coronary atherosclerosis, angina pectoris and respiratory symptoms after COVID-19 infection?</td>
<td>ELVIS</td>
</tr>
<tr>
<td>NA</td>
<td>6. What is the level of functioning during the course of disease in patients following a rehabilitation programme after COVID-19-related ICU admission?</td>
<td>Adelante</td>
</tr>
</tbody>
</table>

CAPACITY-COVID, Cardiac complications in patients with COVID-19 cohorts; DC&TC cohort, Dutch COVID and Thrombosis Consortium cohort; COVAS, Bernhoven Early detection of Vascular damage after COVID-19 cohort; ELVIS, ZuydErLand COVID-19 registry; ICU, intensive care unit; MaastrICht, Maastricht Intensive Care COVID cohort; NA, not applicable; POPCorrn, POPulation health impact of the COVID-19 pandemic.

WP4 will address the fifth study aim: developing and testing a patient platform prototype. As the patient platform will be connected to the digital questionnaire platform, individual CORFU questionnaire responses can be presented individually to the corresponding patient. It offers the possibility for patients to consult their own situation, compare this with the past and with the situation of similar patients, profit from suggestions of other patients in similar situations, and gain insight into their future health. The specific content (eg, which symptom domains and other domains of interest) to be presented in the patient platform will be based on focus groups with healthcare professionals, (former) patients and patient representatives. Patient platforms aim to increase empowerment and reassurance (outcomes tested) and might provide guidance in healthcare-seeking and self-care. By providing feedback on the given answers, the platform increase patients’ knowledge and self-consciousness about the potential existence of long COVID-19 symptoms and change over time, thereby putting them in own data-driven control on their health situation.

Sample size calculation
The sample size for this study is established pragmatically. A heterogeneous sample of COVID-19 patients is included by choosing different cohorts with considerable heterogeneity in the severity of the disease, national coverage and without any exclusion criteria. This resulted in a collection of seven small to very large cohorts. Our
sample size calculations of WP1, WP2 and WP3 are based on the smallest subgroup of patients that will be analysed in this study.

First, for estimating the prevalence of long COVID symptoms (WP1), for the least favourable percentage of 50% (the variance of a percentage is highest at 50%), the maximum width of the 95% CI will be approximately plus and minus 5%. For all other percentages, the CI will be even smaller. Second, for investigating the pathophysiological mechanisms that may cause long COVID symptoms (WP2), there will be sufficient power to detect associations with symptom severity, expressed in standardised effect size (Cohen’s d) of 0.3, with a power of 80% and a type-I error of 5%. Third, for the development of a prediction model for long COVID complaints (WP3), we anticipate a large number of cases, taking into account that 57% of patients suffered from at least one long COVID complaint up to 6 months after infection.15 Depending on the response rate and resulting sample size, we will determine the maximum number of candidate predictors we can use for multivariable modelling with the method of Riley et al, allowing a maximum shrinkage of predictor coefficients of 0.9.23

Statistical tests or estimations are not part of WP4. Therefore, sample size or statistical power calculations are not applicable for WP4.

**Patient and public involvement**

Patient organisations (family and patient centred intensive care, IC Connect and the ‘Hartenraad’) and patients of the Maastricht University Medical Centre+ (MUMC+) intensive care panel were involved in the design of the CORFU study. Patients were involved in the development and testing of the international basic questionnaire on persistent symptoms after COVID-19, which serves as the basis for the CORFU questionnaire. In addition, patients provided feedback on the phrasing of questions, the fill-out time of the questionnaire and the willingness to fill out the questionnaire periodically. Participants will be able to provide feedback on the (missing) content of the CORFU questionnaire through an open-ended question. Comments will be discussed and implemented prospectively when deemed relevant, making the CORFU questionnaire a continuously developing measurement instrument.

Patients will have an advisory role in developing the patient platform prototype (WP4), which allows patients to digitally consult their answers in real time and compare them with reference populations. In addition, advice will be asked on the (type of) provided feedback questions, the formatting and visualisation of answers, and the relevant reference groups to be considered. Eventually, CORFU findings will be presented in a lay summary, and a flyer on long COVID will be developed in close collaboration with patients. The dissemination strategy of CORFU findings and the long COVID flyer will be based on patient and public preferences, in which also the involved patient organisations will have an important role.

**DISCUSSION**

The CORFU study has the opportunity to investigate the prevalence, pathophysiological mechanisms, and prediction of long COVID, and its relationship with health-related quality of life. CORFU will aggregate data from seven existing COVID cohorts and will enrich the data with prospective follow-up of long COVID outcomes and determinants up to a maximum of 2 years after acute infection. A prediction model and patient platform prototype will be developed to guide future patient care.

Estimation of the prevalence of long COVID symptoms up to 2 years after infection will be based on the multidimensional CORFU questionnaire, including physical and psychological complaints after COVID. The extensive set of physical complaints gives the opportunity to study symptoms in great detail. The additional focus on psychological impact addresses the call to take COVID psychopathology into account when designing new studies. It reflects the current knowledge that mental well-being is worse in patients who suffered from COVID compared with healthy respondents, and that there is a high rate of mental health complaints up to 1 year after acute infection.27-34

CORFU findings may be used to inform national and international guidelines on diagnostics, treatment and follow-up of long COVID and contribute to developing a (new) more accurate long COVID definition, likely differentiating long COVID phenotypes. Available guidelines and definitions on long COVID are currently, as expected, based on short-term follow-up studies, whereas CORFU will report long COVID symptoms up to 2 years after infection.35 Besides, the current WHO long COVID definition remains broad and unspecific, thereby lacking accurate differentiation of its heterogeneous appearance into clinical phenotypes. Defining such phenotypes with potentially adding clinical parameters (biomarkers, imaging, etc) might enhance clinical workability, and thereby diagnostics, and the development of tailored therapies based on underlying pathophysiology.

An important strength of the CORFU study is that data will be aggregated from seven cohorts of (former) COVID-19 patients. Due to mortality and non-response, the effective number might be slightly lower. Nevertheless, the large CORFU sample size allows for robust analysis. Furthermore, the difference in designs of the cohorts allows us to answer study aims for various subgroups (eg, COVID-19 at home vs hospitalised (ward and/or ICU)) and to test multiple, detailed, pathophysiological hypotheses, depending on the characteristics of the patients included in the participating cohorts, also related to COVID-19 variants by using wave at the time of infection as a surrogate marker. Furthermore, the ability to aggregate data of multiple cohorts is an efficient way of (close) national collaboration which contributes to more robust and reliable findings compared with multiple, parallel, single cohort studies with smaller sample sizes.

Another strength is that CORFU will use data from a large control group of respondents who did not suffer
from COVID-19. This allows the comparison of the prevalence of long COVID-19 symptoms with the prevalence of these symptoms in the general Dutch, non-COVID-19 population, potentially highlighting the secondary impacts of the pandemic. This is a crucial comparison currently lacking in the majority (79%) of long COVID-19 research but required to identify and quantify attributable symptoms objectively. For instance, the (social) restrictions may significantly impact the quality of life and (mental) well-being of the general population. These factors need to be considered when analysing and interpreting the CORFU findings. Lastly, as part of WP4, patients will receive personalised feedback on their own questionnaire outcomes and those of other patients in similar situations.

Potential limitations of the CORFU study also merit consideration. First, combining data from seven cohorts is challenging. As each cohort has specific study aims regarding the pathophysiological processes causing long COVID symptoms, not all cohorts collect the same (clinical) information from their participants. To ensure that data from all cohorts can be integrated and that between-cohort comparisons are possible, a minimal set of variables was (post-hoc) harmonised among the participating cohorts regarding background characteristics (eg, sociodemographics, employment status, social, economic status, cultural background), comorbidities and potential confounders. Furthermore, to optimise the data integration process, data received from the cohorts will be transferred into a machine-readable metadata scheme prior to merging the various datasets. Second, there will be an over-representation of (former) COVID patients admitted to the hospital ward and/or ICU compared with those who suffered from COVID at home. This affects estimations of long COVID prevalence, which can be evaluated by post-hoc stratification using community-based cases. The epidemiological basis used for the statistical models to develop prediction models is independent of inpatient/outpatient distribution and depends solely on the associations and interactions found within specific patient groups, as COVID severity will be added as a covariate. Moreover, analyses will be stratified by disease severity for subgroup-specific conclusions. Third, especially in the first COVID wave (1 March 2020–30 June 2020) for non-hospitalised patients, not all suspected COVID cases were tested due to capacity and test-material constraints in the Netherlands. For CORFU, this means that there is a lack of confirmed infections for participants of the community-based POPCORN cohort who self-reported to have (likely) suffered from COVID based on an unspecified positive test or the presence of COVID-19-related symptoms. In order to reduce the impact of this limitation, the primary analyses will be repeated in the sensitivity analyses on the subgroup of COVID cases with a confirmed infection. The same holds for controls from the POPCORN cohort who (likely) did not suffer from COVID: there is a possibility that these controls did suffer from COVID, but that they, for example, did not test due to the absence of symptoms or test-material constraints, or that their tests were false negative (online supplemental table S1). This might result in some misclassification of cases that had no or only very mild symptoms, never got tested, and will likely report never having suffered from COVID. This will be described when reporting CORFU study results, and, when deemed relevant, additional (stratified) analyses will be conducted.

Ethics and dissemination

This study will be conducted according to the latest update of the Declaration of Helsinki and is registered at ClinicalTrials.gov (NCT05240742). Ethics approval was obtained from the medical research ethics committee (MREC) of Maastricht University Medical Center+ and Maastricht University (committee reference number METC2021-2990) and the local MRECs of the participating cohorts (online supplemental table S2). Participants will be asked for written or digital informed consent, by the cohort in which they are participating, prior to administering the first CORFU questionnaire and will be informed that participation is voluntary. Data will be made available (Open Science/FAIR) subject to ethical approval and standard access and anonymisation procedures.

Author affiliations

1Department of Cardiology, Maastricht UMC+, Maastricht, The Netherlands
2Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands
3Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht UMC+, Maastricht, The Netherlands
4Intensive Care Medicine, Maastricht UMC+, Maastricht, The Netherlands
5Department of Obstetrics and Gynaecology, Maastricht UMC+, Maastricht, The Netherlands
6Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
7Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
8Institute of Cardiovascular Science, Faculty of Population Health Sciences, Health Data Research UK and Institute of Health Informatics, University College London, London, UK
9Scientific Department, EuroHeart Research Foundation, Rotterdam, The Netherlands
10Department of Genetics, University Medical Centre Groningen, Groningen, The Netherlands
11Department of Intensive Care, Maastricht UMC+, Maastricht, The Netherlands
12Department of Family Medicine, Maastricht University, Maastricht, The Netherlands
13Care and Public Health Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
14Department of Biochemistry, Department of Internal Medicine, Thrombosis Expert Centre, Maastricht, The Netherlands
15Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands
16Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
17Department of Rehabilitation Medicine, Functioning, Participation & Rehabilitation, Maastricht University, Maastricht, The Netherlands
18Department of Intensive Care, Maastricht University Medical Centre+, Maastricht, The Netherlands
19Department of Cardiology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands
20Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota, USA
21Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
Contributors BCTvB, BH, BLJHK, CG-D, EB, FAK, FWA, GJB, HTC, ICCvdH, JH, JWLc, KV, MW and SMJvk conceived and designed the study. CG-D, DK, EBNJJ, MSJNW, SCMH and SMJvk drafted the manuscript. BCTvB, BH, BLJHK, EB, FAK, FWA, GJB, HTC, ICCvdH, JH, JWLc, KV, LW, MW, MDdk, ML, RW and Svs critically reviewed the manuscript. All authors read and approved the final manuscript.

Funding This work is supported by The Netherlands Organization for Health Research and Development (ZonMW), grant number 10430302110005, and an unrestricted grant has been received from the EuroQol Research Foundation. Individual COVID-19 cohorts contributing to the CORFU study may have been funded independently from this grant.

Competing interests BCTvB, BH, BLJHK, JH, DK, EB, EBNJJ, GJB, ICCvdH, JH, JWLc, LW, MSJNW, MW, RW, SCMH, SMJvk, Svs and BH declare no competing interests. FAK received research support from Bayer, SMS, Boehringer-Ingelheim, MSD, Daiichi-Sankyo, Actelion, Boston Scientific, The Netherlands Organization for Health Research and Development (ZonMW), The Dutch Thrombosis Association, and The Dutch Heart Foundation. FWA is supported by the National Institute of Health Research University College London Hospitals Biomedical Research Centre. For the CAPACITY-COVID cohort participating in CORFU, FWA and ML received support from Dutch Heart Foundation (2020B006 CAPACITY) on The Netherlands Organization for Health Research and Development (ZonMW) (grant number 10430102110006 DEFENCE). HTC received support from Bayer, received consulting fees from Pfizer, Leo, Alveran, Viatris, Astra Zeneca, and Galapagos, and has stock (options) in Coagulation Profile. KV has royalties or licences for Philips, Medtronic, Abbott, and Biosense Webster, received consulting fees from Philips, Biosense Webster, Boston Scientific, and Medtronic, and has a role in the European Heart Rhythm Association congress organization and digital committee. MDdk received a presentation fee from Glaxo Smith Kline. ML is supported by the Alexander Suerman Stipend of the University Medical Center Utrecht.

Patient and public involvement Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc-4.0/.

ORCID ids Dorte Heiskanen http://orcid.org/0000-0003-1172-8498
Stella C Meeks http://orcid.org/0000-0002-1221-1304
Bas C van Bussel http://orcid.org/0000-0003-1621-7848
Jochen W L Cals http://orcid.org/0000-0001-9585-5674
Iwan C van der Horst http://orcid.org/0000-0003-3891-8522
Sander M J van Kuijk http://orcid.org/0000-0003-2796-729X

REFERENCES
Open access


